Morbidity, risk of cancer and mortality in 3645 HFE mutations carriers.
Hannes HagströmNelson NdegwaMolly JalmeusMattias EkstedtIris PosserudFredrik RorsmanNils NyhlinDaniel KlintmanMårten WernerHanns-Ulrich MarschallJohan AsklingPer Stålnull nullPublished in: Liver international : official journal of the International Association for the Study of the Liver (2021)
Individuals found to be HFE mutation carriers in a university hospital setting had an increased risk for mortality in men, along with increased risks of cirrhosis, HCC, diabetes type 2, and osteoarthritis. In general, the absolute risk for adverse outcomes was low and no increased risk for colon or breast cancer was observed.